WALTHAM,
Mass., Feb. 19, 2025 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a
clinical-stage biotechnology company advancing best-in-class
antibody engineering, dose optimization, and rational therapeutic
combinations for the treatment of Inflammatory Bowel Disease
("IBD") and other immune-mediated diseases, today announced a
poster presentation at the 20th Congress of the European
Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025, in Berlin, Germany, showing that combined
inhibition of α4β7 integrin and TL1A cytokine is superior to either
monotherapy in mouse models of colitis and coadministration
demonstrates no drug-drug effects on exposure in non-human primates
(NHPs).
"We are thrilled to share these recent preclinical findings
supporting the combination potential for our SPY120 program
(anti-α4β7 and anti-TL1A). We tested mouse surrogates of SPY120 in
two in vivo models of IBD, demonstrating that combined
inhibition of the α4β7 integrin and TL1A cytokine provide additive
or greater than additive efficacy relative to inhibition of either
target alone," said Andy Spencer,
PhD, SVP of Preclinical R&D at Spyre. "Further, the
pharmacokinetic profiles of our SPY001 and SPY002 antibodies in
NHPs were similar when dosed as monotherapies or in combination,
indicating the potential for quarterly or twice-annual dosing of
SPY120 in humans. Together, these results demonstrate the potential
for SPY120 to have best-in-indication efficacy and convenience in
IBD, complementing our previously disclosed preclinical results for
SPY130 (anti-α4β7 and anti-IL-23) and SPY230 (anti-TL1A and
anti-IL-23). We look forward to testing all three potential
best-in-indication combinations in our Phase 2 trial in ulcerative
colitis patients which is expected to begin mid-year."
The poster will be available for viewing during the ECCO
Congress beginning on February 19,
2025, and details are as follows:
Title: Combined inhibition of TL1A and integrin β7 is
superior to either monotherapy in mouse models of colitis and
coadministration of SPY001 and SPY002 demonstrates no drug-drug
effects on exposure in non-human primates
Authors: M Siegel, J Friedman, D Nguyen, J
McNally, M Kennedy, O Ballew, M Rose, A
Spencer
Full session details can be accessed via the ECCO program.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to
create next-generation inflammatory bowel disease (IBD) and other
immune-mediated disease products by combining best-in-class
antibody engineering, dose optimization, and rational therapeutic
combinations. Spyre's pipeline includes extended half-life
antibodies targeting α4β7, TL1A, and IL-23. For more information,
visit Spyre's website at www.spyre.com.
Forward-Looking Statements
Certain statements
in this press release, other than purely historical information,
may constitute "forward-looking statements" within the meaning of
the federal securities laws, including for purposes of the safe
harbor provisions under the United States Private Securities
Litigation Reform Act of 1995, concerning Spyre and other matters.
These forward-looking statements include, but are not limited to,
express or implied statements relating to Spyre's management team's
expectations, hopes, beliefs, intentions or strategies regarding
the future including, without limitation, Spyre's ability to
achieve the expected benefits or opportunities with respect to its
pipeline of product candidates such as potential dosing regimens of
SPY120 in humans; the potential for SPY120, SPY130 and SPY230 to be
best-in-indication combinations, including the potential for SPY120
to have best-in-indication efficacy and convenience in IBD; Spyre's
future clinical development activities, including its planned Phase
2 trial in ulcerative colitis and timing thereof; the potential
therapeutic benefits of Spyre's product candidates as monotherapies
and or in combination; and the timing and results of clinical
trials. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking statements. The words "opportunity," "potential,"
"milestones," "pipeline," "can," "goal," "aim," "strategy,"
"target," "seek," "anticipate," "achieve," "believe,"
"contemplate," "continue," "could," "estimate," "expect,"
"intends," "may," "might," "plan," "possible," "predict,"
"project," "should," "will," "would," "slated" and similar
expressions (including the negatives of these terms or variations
of them) may identify forward-looking statements, but the absence
of these words does not mean that a statement is not
forward-looking. These forward-looking statements are based on
current expectations and beliefs concerning future developments and
their potential effects. There can be no assurance that future
developments affecting Spyre will be those that have been
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond Spyre's control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited those uncertainties and factors described under
the heading "Risk Factors" and "Note about Forward-Looking
Statements" in Spyre's most recent Quarterly Report on Form 10-Q
filed with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors included in other
filings by Spyre from time to time. Should one or more of these
risks or uncertainties materialize, or should any of Spyre's
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Nothing in this press release should be regarded as a
representation by any person that the forward-looking statements
set forth therein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You
should not place undue reliance on forward-looking statements in
this press release, which speak only as of the date they are made
and are qualified in their entirety by reference to the cautionary
statements herein. Spyre does not undertake or accept any duty to
make any updates or revisions to any forward-looking statements.
This press release does not purport to summarize all of the
conditions, risks and other attributes of an investment in
Spyre.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-poster-presentation-at-the-20th-congress-of-the-european-crohns-and-colitis-organisation-302379930.html
SOURCE Spyre Therapeutics, Inc.
